Abstract

Xeris Pharmaceuticals Inc will report its quarterly results on May 07, 2026 Pre-Market; our preview summarizes consensus revenue, profitability, and EPS expectations alongside company guidance, and highlights the product revenue trajectory and near-term drivers.

Market Forecast

For the upcoming quarter, the market projects Xeris Pharmaceuticals Inc to deliver revenue of 79.99 million US dollars, an estimated year-over-year increase of 38.85%, with EBIT projected at 4.28 million US dollars and EPS at -0.01; margin and EPS forecasts point to mixed profitability dynamics compared with the prior year, while year-over-year growth is expected to be positive for revenue and EBIT. The main business remains product sales, with a strong trajectory supported by broad-based demand; the most promising segment is product sales, which previously generated 283.00 million US dollars in annualized revenue with robust momentum.

Last Quarter Review

In the previous quarter, Xeris Pharmaceuticals Inc recorded revenue of 85.81 million US dollars, a gross profit margin of 87.24%, net profit attributable to the parent company of 11.08 million US dollars, a net profit margin of 12.91%, and adjusted EPS of 0.06, with revenue growing 42.78% year over year. A key highlight was significant profitability expansion, where net profit improved sharply quarter on quarter by 1,684.38%, reflecting operating leverage and cost control. Main business momentum was anchored by product sales at 283.00 million US dollars on an annualized basis, complemented by 8.84 million US dollars from licenses and other income.

Current Quarter Outlook

Main commercial franchise

Xeris Pharmaceuticals Inc’s core revenue engine is its product sales franchise, which includes its commercialized therapeutics portfolio. The previous quarter’s 85.81 million US dollars in revenue and 87.24% gross margin establish a high-value revenue base that can support positive operating contribution as opex intensity moderates. For this quarter, revenue is expected at 79.99 million US dollars, implying normal seasonality versus the prior quarter but a 38.85% increase versus the year-ago period, which should keep absolute gross profit elevated given the high gross margin profile. The combination of revenue scale and gross margin should allow EBIT to remain positive at 4.28 million US dollars even as EPS is forecast at a modest loss, indicating that non-operating items and below-the-line expenses may weigh on reported EPS.

Growth platform within the portfolio

The most promising contributor remains product sales, which constituted roughly 97% of revenue mix based on the latest reported period and totaled 283.00 million US dollars on an annualized basis, with licenses and other contributing 8.84 million US dollars. This mix underscores the company’s dependence on commercial uptake and formulary access across its marketed products, and the year-over-year revenue growth forecast of 38.85% suggests continued prescription volume gains and/or pricing durability. Sustained gross margin near the high 80% range enhances operating leverage potential if sales continue to scale, providing room for profit expansion if operating expenses grow slower than revenue.

Key stock-price swing factors this quarter

Investor focus is likely to concentrate on the durability of revenue growth, the trajectory for gross margin, and the path to sustained GAAP profitability. A print near the 79.99 million US dollars revenue estimate, coupled with gross margin holding near recent levels, would validate the revenue quality and support positive EBIT, while any deviation in margin could materially impact operating income given the high conversion from gross profit to EBIT. On EPS, consensus at -0.01 highlights sensitivity to non-operating items such as interest expense and fair-value adjustments; clearer signals on deleveraging or financing costs could drive sentiment. Management’s commentary on demand trends across its core prescription products, inventory normalization, and any updates to full-year guidance will likely shape post-report performance.

Analyst Opinions

Across recently published views, the prevailing stance trends positive, with a majority of commentaries highlighting revenue growth durability and improving operating metrics, while a minority notes EPS volatility. Representative opinions emphasize that the revenue estimate of 79.99 million US dollars implies healthy year-over-year expansion and that EBIT returning to a projected 4.28 million US dollars supports the profitability pathway. Analysts also point to the previous quarter’s 42.78% revenue growth and 0.06 adjusted EPS beat versus estimates as constructive signals into this report. On balance, the majority view expects revenue to meet or modestly exceed the forecast and sees operating performance as resilient, though bottom-line GAAP EPS could hover around breakeven due to below-the-line factors.